中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

139 records (took 0.054 seconds)

    CHIMERIC CLOTTING FACTORS
    32.
    发明申请
    CHIMERIC CLOTTING FACTORS 审中-公开
    CHIMERIC切割因子

    公开(公告)号：US20150353911A1

    公开(公告)日：2015-12-10

    申请号：US14406160

    申请日：2013-06-07

    Applicant: Biogen Idec MA Inc.

    Inventor： Joe Salas ,  Elena Kistanova ,  Vu Phong Hong ,  Adam R. Mezo ,  Robert T. Peters

    IPC: C12N9/64 ,  A61K38/48 ,  A61K47/48

    CPC classification number: C12N9/6432 ,  A61K38/36 ,  A61K38/4846 ,  A61K47/62 ,  C12N9/6437 ,  C12Y304/21006 ,  C12Y304/21021

    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.

    Abstract translation: 本发明提供了包含可激活的凝血因子和增强子部分的嵌合凝血因子。 可激活的凝血因子允许嵌合凝血因子在凝血部位被活化。 增强子部分可另外改善嵌合凝血因子的促凝活性。 通过与半衰期延长剂的融合进一步改善嵌合凝血因子，这提高了嵌合凝血因子的药代动力学性质。 本发明还包括制备方法和使用这些嵌合凝血因子的方法。

    PROCOAGULANT COMPOUNDS
    37.
    发明申请
    PROCOAGULANT COMPOUNDS 审中-公开
    方案化合物

    公开(公告)号：US20150184142A1

    公开(公告)日：2015-07-02

    申请号：US14406163

    申请日：2013-06-07

    Applicant: Biogen Idec MA Inc.

    Inventor： Vu Phong Hong ,  Adam R. Mezo ,  Joe Salas ,  Robert Peters

    IPC: C12N9/64 ,  A61K38/48

    CPC classification number: C12N9/6437 ,  A61K38/02 ,  A61K38/36 ,  A61K38/4846 ,  C12N9/6432

    Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.

    Abstract translation: 本公开提供了包含促凝血多肽，例如促凝血肽和/或凝血因子的蛋白酶活化的促凝血化合物，以及包含蛋白酶切割底物（例如，合成凝血酶底物）和自发性隔离物（例如， ，对氨基苄基氨基甲酸酯）。 在通过蛋白酶（例如凝血酶）裂解蛋白酶可切割底物之后，自消除性间隔区从促凝血多肽切割自身，使得多肽处于未衍生的和活性的形式。 还提供了药物组合物，使用所公开的化合物治疗出血性疾病的方法，增强促凝血多肽的体内功效的方法，增加包含促凝血多肽的化合物的蛋白水解切割的功效的方法，活化促凝血多肽的方法和释放方法 来自异源部分如PEG的促凝血多肽。

    Sp35 antibodies and uses thereof
    39.
    发明授权
    Sp35 antibodies and uses thereof 有权
    Sp35抗体及其用途

    公开(公告)号：US09066984B2

    公开(公告)日：2015-06-30

    申请号：US13841351

    申请日：2013-03-15

    Applicant: Biogen Idec MA Inc.

    Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Christilyn Graff

    IPC: A61K39/395 ,  A61K39/00 ,  A61K35/30 ,  A61K47/48 ,  C07K16/18 ,  C07K16/28 ,  C12N15/113

    CPC classification number: A61K47/48538 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1138 ,  C12N2310/111 ,  C12N2310/14

    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

    Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成（负调节因子）的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。

Patent Agency Ranking